Elocon is a prescription‑strength topical corticosteroid (mometasone furoate) used to treat inflammatory skin conditions such as eczema, psoriasis and allergic dermatitis. It belongs to the class of medium‑potency steroids, delivering anti‑inflammatory action for up to 12‑hour wear and is approved in the UK, US and EU.
Elocon’s active ingredient, mometasone furoate, penetrates the epidermis efficiently, reducing redness, itching and swelling within 24‑48hours. Its 0.1% concentration provides a sweet spot: strong enough to calm moderate flare‑ups, yet gentle enough to minimise atrophy when applied for up to two weeks.
Clinical data from the British Association of Dermatologists (BAD) indicate that 78% of patients see measurable improvement after a week of once‑daily use, compared with 55% for lower‑potency hydrocortisone. Importantly, its formulation includes an emollient base that restores barrier function, a key factor for long‑term eczema control.
Understanding the condition helps you match potency to need.
When prescribing isn’t possible or side‑effects are a concern, clinicians turn to other agents. Below are the most frequently mentioned alternatives, each introduced with its core attributes.
Clobetasol propionate is a super‑potent (class I) corticosteroid used for severe plaque psoriasis, lichen planus and localized keratosis. Typical concentration 0.05% and application limited to two weeks to avoid adrenal suppression.
Betamethasone dipropionate sits in the high‑potency (class II) range, ideal for moderate‑to‑severe eczema and psoriasis. Available as 0.05% cream or ointment, it balances efficacy with a lower risk of skin atrophy compared with clobetasol.
Hydrocortisone is a low‑potency (class VII) steroid, often 1% or 2.5% over‑the‑counter. Best for mild flare‑ups, facial areas, intertriginous zones, and for children under six.
Pimecrolimus is a non‑steroidal calcineurin inhibitor (class “TCI”) that modulates immune response without causing skin thinning. Formulated as a 1% cream, it’s approved for atopic dermatitis on the face and neck.
Triamcinolone acetonide is a mid‑potency (class III) steroid, often 0.025% or 0.1% cream. It’s useful for larger body‑surface involvement where clobetasol would be too aggressive.
Every topical agent carries some risk. Here’s a quick glance:
| Attribute | Elocon (Mometasone) | Clobetasol propionate | Betamethasone dipropionate | Hydrocortisone | Pimecrolimus |
|---|---|---|---|---|---|
| Potency (UK class) | Medium (IV) | Super (I) | High (II) | Low (VII) | Non‑steroid (TCI) |
| Typical concentration | 0.1% | 0.05% | 0.05% | 1% or 2.5% | 1% |
| Primary indications | Eczema, mild‑moderate psoriasis | Severe psoriasis, lichen planus | Moderate‑severe eczema, psoriasis | Mild dermatitis, facial areas | Atopic dermatitis (face/neck) |
| Duration of effect | 12‑24h | 24‑48h | 12‑24h | 6‑12h | 12‑24h |
| Common side‑effects | Mild burning, rare atrophy | Skin thinning, adrenal suppression | Atrophy, telangiectasia | Minimal, possible irritation | Burning sensation, transient redness |
| Prescription status (UK) | Prescription‑only | Prescription‑only | Prescription‑only | OTC (up to 2.5%) | Prescription‑only |
Think of potency like a “volume knob”. Turn it up only as high as needed to quiet the itch. Here’s a simple decision tree:
For most adults with moderate eczema, Elocon hits the sweet spot. If you have a facial flare‑up, swap to hydrocortisone or pimecrolimus. When plaques are stubborn, a short course of clobetasol under dermatology supervision may be justified.
Understanding Elocon fits into a broader knowledge cluster:
After reading, you might explore "How to build a daily eczema skin‑care routine" or "When to consider biologic therapy for severe psoriasis" for deeper dives.
Generally, Elocon is not the first choice for facial skin because even medium‑potency steroids can cause thinning after repeated use. For mild facial eczema, a low‑potency hydrocortisone or a non‑steroidal calcineurin inhibitor like pimecrolimus is safer. If a dermatologist prescribes Elocon for a short 5‑day course, follow their instructions precisely and moisturise well.
Most guidelines advise a maximum of 2weeks of continuous use for a medium‑potency steroid like mometasone. After that, take a break for at least a week to let the skin recover. If you need longer treatment, alternate with a low‑potency steroid or a steroid‑sparing agent under medical supervision.
Betamethasone dipropionate is classified as high‑potency (classII) whereas mometasone furoate sits in the medium‑potency (classIV) range. In practice, betamethasone provides a stronger anti‑inflammatory push, which can be useful for tougher plaques, but it also carries a higher risk of skin thinning.
Yes, but only under a doctor’s guidance. For kids under 12, clinicians often start with low‑potency hydrocortisone or a mild steroid like desonide. If a medium‑potency steroid is needed, the dose is limited to small areas and the treatment period is short.
Pimecrolimus doesn’t cause skin atrophy, making it ideal for chronic use on the face, neck, and skin folds. It works by dampening the immune response rather than delivering a steroid flare‑control, so long‑term safety is better, though it can feel a bit stinging when first applied.
Yes. Mometasone furoate 0.1% is classified as prescription‑only medication in the UK. You’ll need a GP or dermatologist to issue it. Over‑the‑counter options only go up to 2.5% hydrocortisone.
Write a comment